Literature DB >> 19393628

Visfatin causes endothelium-dependent relaxation in isolated blood vessels.

Hideyuki Yamawaki1, Naoko Hara, Muneyoshi Okada, Yukio Hara.   

Abstract

Visfatin is a novel adipocyte-derived cytokine. We hypothesized that visfatin could directly affect vascular reactivity. To test the hypothesis, effects of visfatin on contraction of isolated blood vessels were examined. In endothelium-intact rat aorta, pretreatment with visfatin (100 ng/ml, 30 min) inhibited noradrenaline (NA; 1 nM-1 microM)-induced contraction. In NA (100 nM)-pre-contracted aorta, visfatin (1-100 ng/ml) directly induced a relaxation. Although an N(G)-Nitro-L-arginine methyl ester (300 microM, 15 min) inhibited the relaxation, an insulin receptor inhibitor, AGL2263 (10 microM, 20 min) was ineffective. Visfatin (100 ng/ml, 20 min) induced a phosphorylation of eNOS at serine 1177 and a de-phosphorylation of eNOS at threonine 495. Visfatin also induced a phosphorylation of Akt at serine 473 and a substrate of cGMP-dependent protein kinase, vasodilator stimulated phosphoprotein at serine 239. Present study revealed for the first time that visfatin has a vasodilating effect on isolated blood vessels, which is mediated via endothelium-derived NO.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19393628     DOI: 10.1016/j.bbrc.2009.04.074

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

1.  Membrane raft-lysosome redox signalling platforms in coronary endothelial dysfunction induced by adipokine visfatin.

Authors:  Min Xia; Chun Zhang; Krishna M Boini; Audrey M Thacker; Pin-Lan Li
Journal:  Cardiovasc Res       Date:  2010-09-07       Impact factor: 10.787

2.  Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: focus on oxidative stress and endothelial progenitor cells.

Authors:  Mohamed I Saad; Taha M Abdelkhalek; Moustafa M Saleh; Maher A Kamel; Mina Youssef; Shady H Tawfik; Helena Dominguez
Journal:  Endocrine       Date:  2015-08-14       Impact factor: 3.633

3.  Gene-gene interactions in the NAMPT pathway, plasma visfatin/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.

Authors:  M R Luizon; A C T Palei; V A Belo; L M Amaral; R Lacchini; G Duarte; R C Cavalli; V C Sandrim; J E Tanus-Santos
Journal:  Pharmacogenomics J       Date:  2016-05-10       Impact factor: 3.550

4.  Cloning and expression of visfatin and screening of oligopeptides binding with visfatin.

Authors:  Xin Yu Liu; Lin Ge; De Min Yu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 5.  Vasodilator signals from perivascular adipose tissue.

Authors:  Maik Gollasch
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 6.  Therapeutic applications of conditioned medium from adipose tissue.

Authors:  Minjia Dai; Yan Zhang; Mei Yu; Weidong Tian
Journal:  Cell Prolif       Date:  2016-08-04       Impact factor: 6.831

Review 7.  Cardiovascular consequences of metabolic syndrome.

Authors:  Johnathan D Tune; Adam G Goodwill; Daniel J Sassoon; Kieren J Mather
Journal:  Transl Res       Date:  2017-01-09       Impact factor: 7.012

Review 8.  Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells.

Authors:  Giovanni Anfossi; Isabella Russo; Gabriella Doronzo; Alice Pomero; Mariella Trovati
Journal:  Mediators Inflamm       Date:  2010-06-28       Impact factor: 4.711

9.  Visfatin correlates with hot flashes in postmenopausal women with metabolic syndrome: effects of genistein.

Authors:  Alessandra Bitto; Vincenzo Arcoraci; Angela Alibrandi; Rosario D'Anna; Francesco Corrado; Marco Atteritano; Letteria Minutoli; Domenica Altavilla; Francesco Squadrito
Journal:  Endocrine       Date:  2016-04-28       Impact factor: 3.633

10.  Visfatin induces oxidative stress in differentiated C2C12 myotubes in an Akt- and MAPK-independent, NFkB-dependent manner.

Authors:  Radu C Oita; Dudley Ferdinando; Steve Wilson; Christopher Bunce; Dawn J Mazzatti
Journal:  Pflugers Arch       Date:  2009-11-08       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.